title: Carfilzomib for the treatment of multiple myeloma.
abstract: Carfilzomib is a second-generation selective proteasome inhibitor that has been recently approved in the use for refractory multiple myeloma. It has been shown to be beneficial in both bortezomib-resistant and bortezomib-naive patients, with a tolerable side effect profile. Peripheral neuropathy is less common in patients receiving carfilzomib compared to bortezomib. Recent and ongoing clinical trials are establishing the role of carfilzomib in the treatment of refractory multiple myeloma.
authors.affiliation: New York University Langone Medical Center, New York, NY, USA.
authors.forename: J
authors.initials: J
authors.lastname: Lue
authors.forename: S
authors.initials: S
authors.lastname: Goel
authors.forename: A
authors.initials: A
authors.lastname: Mazumder
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001897:Boronic Acids / Q000494:pharmacology; D000069286:Bortezomib; D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D009842:Oligopeptides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011719:Pyrazines / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D009842:Oligopeptides; D011719:Pyrazines; D000069286:Bortezomib; C524865:carfilzomib
keywords: Carfilzomib; Multiple myeloma; Proteasome inhibitor